Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer

15 Feb 2018

The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.

Pfizer Inc. and Merck KGAAreported a Phase III failure for their PD-L1 inhibitor Bavencio (avelumab) in second-line non-small cell lung cancer on Feb. 15, which at least one analyst sees as portending a poor outcome for an ongoing Phase III study in the first-line setting for this tumor type.

The checkpoint inhibitor failed, in the 792-patient JAVELIN Lung 200 study, to meet its primary endpoint of improving overall survival (OS) compared to a control arm of docetaxel chemotherapy in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.